Mangoceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Mangoceuticals, Inc. (MGRX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$1.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- Mangoceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$1.31M, a 12932.40% decline year-over-year.
- Mangoceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $10.22K.
- Mangoceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$723.63K, a 122.70% decline year-over-year.
- Mangoceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $3.19M.
- Mangoceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $1.42M.
- Mangoceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$670.51K, a 1294.22% decline from fiscal 2023.
- Mangoceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $56.15K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.25M 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | -$1.31M 10-Q · filed 2026-05-19 | ||||
| 2025-12-31 | $1.42M 10-K · filed 2026-04-01 | ||||
| 2025-09-30 | $414.86K 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | $34.55K 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | $10.22K 10-Q · filed 2026-05-19 | $10.22K 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | -$670.51K 10-K · filed 2026-04-01 | ||||
| 2024-09-30 | -$663.43K 10-Q · filed 2025-11-14 | ||||
| 2024-06-30 | -$247.60K 10-Q/A · filed 2025-11-14 | ||||
| 2024-03-31 | -$723.63K 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | $56.15K 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $553.89K 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | $2.26M 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | $3.19M 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |